CenterBook Partners’s Definium Therapeutics DFTX Stock Holding History

CenterBook Partners’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$346K	Sell	9,104 -32,151	-78%	-$1.35M	0.02%	732
2026 Q2	$1.94M	Sell	41,255 -1,574	-4%	-$38.9K	0.1%	238
2026 Q1	$809K	Sell	42,829 -95,986	-69%	-$1.63M	0.04%	388
2025 Q4	$1.86M	Sell	138,815 -20,606	-13%	-$255K	0.09%	273
2025 Q3	$1.88M	Buy	+159,421	New	+$1.49M	0.09%	263

Other funds holding DFTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

CenterBook Partners's DFTX Position: Q3 2026 in Review

CenterBook Partners reduced its Definium Therapeutics (DFTX) stake by 78% in Q3 2026, selling an estimated $1.35M and leaving 9,104 shares worth $346K. The position accounts for 0.02% of the portfolio, ranked #732.

CenterBook Partners first reported a position in DFTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $1.94M in Q2 2026. 133 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

CenterBook Partners held 9,104 shares of Definium Therapeutics worth $346K as of Q3 2026.
CenterBook Partners sold 32,151 Definium Therapeutics shares in Q3 2026, an estimated $1.35M.
Definium Therapeutics made up 0.02% of CenterBook Partners's portfolio in Q3 2026, its #732 holding.
CenterBook Partners first reported a position in Definium Therapeutics in Q3 2025 and has held it in 5 quarters since.
CenterBook Partners's Definium Therapeutics position peaked at $1.94M in Q2 2026.
133 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.